A Clinical Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride for Sedation/Anesthesia During Gastroscopy/Colonoscopy

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
GastroscopyColonoscopy
Interventions
DRUG

ET-26HCl 0.8mg/kg group

The initial dose was 0.8 mg/kg administered as a single IV infusion over a period of 1 minute ±5 seconds. If needed, up to 50% of the starting dose was increased (30-seconds ± 5-seconds bolus)

DRUG

Etomidate Injectable Product 0.3mg/kg group

The initial dose was 0.3 mg/kg administered as a single IV infusion over a period of 1 minute ±5 seconds. If needed, up to 50% of the starting dose was increased (30-seconds ± 5-seconds bolus)

Trial Locations (6)

100034

Peking University First Hospital, Beijing

518020

Shenzhen People's Hospital, Shenzhen

610041

West China Hospital of Sichuan University, Chengdu

610072

Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital, Chengdu

628017

Guangyuan First People's Hospital, Guangyuan

644000

Yibin Second People's Hospital, Yibin

Sponsors
All Listed Sponsors
lead

Ahon Pharmaceutical Co., Ltd.

OTHER

NCT06858852 - A Clinical Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride for Sedation/Anesthesia During Gastroscopy/Colonoscopy | Biotech Hunter | Biotech Hunter